Contact
searchSearch
HMP Global
Login

Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Specialty Channel
News
GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia
09/15/2026
Emily Estrada
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated...
09/15/2026
Oncology
News
Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia
09/15/2026
Emily Estrada
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase...
09/15/2026
Oncology
News
Ropeginterferon Alfa-2b Achieves Increasing Complete Hematologic Response Rates With Longer Treatment in Patients With Myeloproliferative Neoplasms
09/15/2026
Emily Estrada
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study...
09/15/2026
Oncology
FDA Approval
FDA Approves First-in-Class Rusfertide to Reduce Phlebotomy Burden in Adult Patients With Polycythemia Vera
08/31/2026
Emily Estrada
The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...
The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...
The FDA has approved rusfertide...
08/31/2026
Oncology
FDA Approval
FDA Approves Ropeginterferon Alfa-2b for Adult Patients With Essential Thrombocythemia
08/31/2026
Emily Estrada
Based on results from the SURPASS ET trial, the FDA has approved ropeginterferon alfa-2b for adult patients with essential thrombocythemia regardless of genotype or disease status, marking the first new FDA-approved treatment for the disease...
Based on results from the SURPASS ET trial, the FDA has approved ropeginterferon alfa-2b for adult patients with essential thrombocythemia regardless of genotype or disease status, marking the first new FDA-approved treatment for the disease...
Based on results from the...
08/31/2026
Oncology
Benjamin Rolles, MD
Conference Coverage
Impact of Treatment Response to Hypomethylating Agents and Time-to-Transplant Status on Outcomes Among Patients With MDS
01/13/2025
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more...
01/13/2025
Oncology
News
Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
Anthony Hunter, MD
Videos
Choosing Interferon Treatment for Patients With Myeloproliferative Neoplasms
10/16/2023
Anthony Hunter, MD
Anthony Hunter, MD, discusses the role of interferon regimens for patients with myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia.
Anthony Hunter, MD, discusses the role of interferon regimens for patients with myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia.
Anthony Hunter, MD, discusses...
10/16/2023
Oncology
Quiz
Hydroxyurea Dosage and Management for Patients With PV
09/25/2023
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a...
09/25/2023
Oncology
News
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis
08/22/2023
Amber Denham
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023
Amber Denham
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology

News

News
GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia
09/15/2026
Emily Estrada
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated...
09/15/2026
Oncology
News
Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia
09/15/2026
Emily Estrada
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase...
09/15/2026
Oncology
News
Ropeginterferon Alfa-2b Achieves Increasing Complete Hematologic Response Rates With Longer Treatment in Patients With Myeloproliferative Neoplasms
09/15/2026
Emily Estrada
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study...
09/15/2026
Oncology
FDA Approval
FDA Approves First-in-Class Rusfertide to Reduce Phlebotomy Burden in Adult Patients With Polycythemia Vera
08/31/2026
Emily Estrada
The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...
The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...
The FDA has approved rusfertide...
08/31/2026
Oncology
FDA Approval
FDA Approves Ropeginterferon Alfa-2b for Adult Patients With Essential Thrombocythemia
08/31/2026
Emily Estrada
Based on results from the SURPASS ET trial, the FDA has approved ropeginterferon alfa-2b for adult patients with essential thrombocythemia regardless of genotype or disease status, marking the first new FDA-approved treatment for the disease...
Based on results from the SURPASS ET trial, the FDA has approved ropeginterferon alfa-2b for adult patients with essential thrombocythemia regardless of genotype or disease status, marking the first new FDA-approved treatment for the disease...
Based on results from the...
08/31/2026
Oncology
Benjamin Rolles, MD
Conference Coverage
Impact of Treatment Response to Hypomethylating Agents and Time-to-Transplant Status on Outcomes Among Patients With MDS
01/13/2025
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more...
01/13/2025
Oncology
News
Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
News
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis
08/22/2023
Amber Denham
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023
Amber Denham
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera
07/14/2023
Gina Tomaine
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology

Interactive Features

Quiz
Hydroxyurea Dosage and Management for Patients With PV
09/25/2023
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a...
09/25/2023
Oncology
Quiz
Cytoreduction and JAK Inhibitors in Patients With Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis
11/30/2022
True or False: Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
True or False: Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
True or False: Both conventional...
11/30/2022
Oncology
Quiz
Quiz: Cytogenic Response Rate of Pemigatinib in Myeloid/Lymphoid Neoplasms Harboring an FGFR1 Arrangement
09/02/2022
The FDA granted approval to pemigatinib to treat adult patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement. In the phase 2 trial which led to the approval, what was the complete cytogenetic response rate...
The FDA granted approval to pemigatinib to treat adult patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement. In the phase 2 trial which led to the approval, what was the complete cytogenetic response rate...
The FDA granted approval to...
09/02/2022
Oncology
idea
Test Your Knowledge
Quiz: Do Antiplatelet, Anticoagulation Therapies Increase Bleeding Risk for MPNs?
02/01/2022
True or false: A retrospective study found antiplatelet and anticoagulation therapies do not increase the risk of bleeding events in patients with MPNs.
True or false: A retrospective study found antiplatelet and anticoagulation therapies do not increase the risk of bleeding events in patients with MPNs.
True or false: A retrospective...
02/01/2022
Oncology
Question marks
Quiz
Quiz: Sotatercept for Anemic Patients With MPN-Associated MF
01/20/2022
True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.
True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.
True or false: A phase 2 study...
01/20/2022
Oncology
writing
Test Your Knowledge
Quiz: Pulmonary Hypertension in Patients With MPNs
01/06/2022
True or false: Findings from a single-center retrospective study investigated the prognostic implication of pulmonary hypertension (PH) in a high-risk MPNs patient population and found PH is associated with worse outcomes.
True or false: Findings from a single-center retrospective study investigated the prognostic implication of pulmonary hypertension (PH) in a high-risk MPNs patient population and found PH is associated with worse outcomes.
True or false: Findings from a...
01/06/2022
Oncology
?
Test Your Knowledge
Quiz: Are DOACs Associated With High Bleeding Rates in MPNs?
12/17/2021
True or false: DOAC’s are associated with high bleeding rates in patients with MPNs.
True or false: DOAC’s are associated with high bleeding rates in patients with MPNs.
True or false: DOAC’s are...
12/17/2021
Oncology
Computer
Test Your Knowledge
Quiz: Does This Inhibitor Therapy Yield Safety in Portal Hypertension MPNs?
12/16/2021
True or false: JAK inhibitor therapy is safe and effective in patients with MPNs complicated by PT without underlying ST.
True or false: JAK inhibitor therapy is safe and effective in patients with MPNs complicated by PT without underlying ST.
True or false: JAK inhibitor...
12/16/2021
Oncology
Test Your Knowledge
Quiz: Mutation Identified as High-Risk Bleeding Factor in MPN
11/29/2021
Which of the following mutations is associated with a higher risk of bleeding in adult patients with MPN?
Which of the following mutations is associated with a higher risk of bleeding in adult patients with MPN?
Which of the following mutations...
11/29/2021
Oncology
qq
Test Your Knowledge
Quiz: Which Mutation Was Identified as High-Risk Bleeding Factor in MPN?
11/11/2021
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations...
11/11/2021
Oncology

Recent News

News
GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia
09/15/2026
Emily Estrada
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated...
09/15/2026
Oncology
News
Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia
09/15/2026
Emily Estrada
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase...
09/15/2026
Oncology
News
Ropeginterferon Alfa-2b Achieves Increasing Complete Hematologic Response Rates With Longer Treatment in Patients With Myeloproliferative Neoplasms
09/15/2026
Emily Estrada
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study...
09/15/2026
Oncology
FDA Approval
FDA Approves First-in-Class Rusfertide to Reduce Phlebotomy Burden in Adult Patients With Polycythemia Vera
08/31/2026
Emily Estrada
The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...
The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...
The FDA has approved rusfertide...
08/31/2026
Oncology
FDA Approval
FDA Approves Ropeginterferon Alfa-2b for Adult Patients With Essential Thrombocythemia
08/31/2026
Emily Estrada
Based on results from the SURPASS ET trial, the FDA has approved ropeginterferon alfa-2b for adult patients with essential thrombocythemia regardless of genotype or disease status, marking the first new FDA-approved treatment for the disease...
Based on results from the SURPASS ET trial, the FDA has approved ropeginterferon alfa-2b for adult patients with essential thrombocythemia regardless of genotype or disease status, marking the first new FDA-approved treatment for the disease...
Based on results from the...
08/31/2026
Oncology
News
Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
News
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis
08/22/2023
Amber Denham
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023
Amber Denham
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera
07/14/2023
Gina Tomaine
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology
News
Ruxolitinib Treatment Effective, Safe for Patients With Newly Diagnosed Polycythemia Vera
05/05/2023
Gina Tomaine
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to...
05/05/2023
Oncology
FDA Approval
FDA Approves and Launches Generic Lanreotide Injection Referencing Somatuline Depot
09/23/2026
Stephanie Holland
The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...
The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...
The FDA approved Amneal’s...
09/23/2026
Oncology
News
NHS-Galleri Trial Finds No Significant Reduction in Stage III or IV Cancer With Multicancer Blood Screening
09/23/2026
Stephanie Holland
Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...
Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...
Results from the randomized...
09/23/2026
Oncology
News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use